CytomX Therapeutics, Inc. - 10-Q Filing
CytomX Therapeutics filed its 10-Q for the quarter ended March 31, 2026, providing updates on its financial position and ongoing collaborations. The filing highlights key agreements with partners such as Amgen, Regeneron, and Astellas, including potential milestone payments and license terms. It also details stock-based compensation plans, including performance-based and time-based restricted stock units, and outlines financial instruments like warrants and private placements.
Tickers: $CTMX